SEATTLE, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted for presentation as detailed below at the 38th EORTC-NCI-AACR (ENA) Symposium 2026 on Molecular Targets and Cancer Therapeutics taking place November 18 to 20, 2026 in Barcelona, Spain. The conference plans to release further details for abstracts on November 4, 2026.
Read on globenewswire.com